Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    20507881 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance
Condition: Leukemia, Myeloid, Chronic, BCR-ABL Positive
Intervention: Drug: Imatinib and Nilotinib

Study has passed its completion date and status has not been verified in more than two years.